Everything below concerns MOD GRF(1-29). We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-12. Numbers and descriptions here follow the published literature rather than marketing material.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
== Treatment == Etoxadrol was intended as an anesthetic for patients requiring particularly long periods of anesthesia for surgery. As an anesthetic, etoxadrol is more potent than ketamine, but less potent than PCP. Etoxadrol is also a potent analgesic. Patients given etoxadrol often reported that they were aware of experiencing pain upon waking from anesthesia, but it did not bother them. Post-operative analgesics are rarely required after patients undergoing surgery are administered etoxadrol. Etoxadrol (along with ketamine, dexoxadrol, and other PCP-like drugs) is an anticonvulsant, preventing tonic seizures in mice that are administered pentylenetetrazol (PTZ), which normally induces seizures.
Some research has shown that sea ice diatoms can use an ancient bacterial metabolic pathway known as the Entner−Doudoroff pathway (EDP) to maintain metabolism and energy production during light limitation. The ability of diatoms to use light for energy also depends on air temperature. As it gets colder, the thylakoid membranes within the microalgae plastids can become dense and compact, which influences how certain photosynthetic proteins (such as the proteins necessary for Photosystems I & II) function and self-assemble. Sea ice diatoms can alter the saturation of the fatty acids that compose the thylakoid membranes as temperatures decrease, which can provide more fluidity to these membranes and result in proper folding of photosynthetic proteins at subzero temperatures. As temperatures within brine pockets decrease, organisms that survive within brine pockets produce substances that can help prevent freezing. Some sea ice diatoms can produce specialized ice-binding proteins and extracellular polymeric substances, which can help increase the habitat space available within a brine pocket by preventing ice formation and reducing the freezing temperature of the brine. Decreased temperatures can also reduce the efficiency of important physiological processes within many microorganisms. Psychrophilic diatoms and bacteria have the ability to regulate their production of proteins, DNA, and enzymes required for metabolism to help maintain metabolic efficiency in colder temperatures.
=== Supercritical fluid chromatography === Supercritical fluid chromatography (SFC) can be used on an analytical scale, where it combines many of the advantages of high-performance liquid chromatography (HPLC) and gas chromatography (GC). It can be used with non-volatile and thermally labile analytes (unlike GC) and can be used with the universal flame ionization detector (unlike HPLC), as well as producing narrower peaks due to rapid diffusion. In practice, the advantages offered by SFC have not been sufficient to displace the widely used HPLC and GC, except in a few cases such as chiral separations and analysis of high-molecular-weight hydrocarbons. For manufacturing, efficient preparative simulated moving bed units are available. The purity of the final products is very high, but the cost makes it suitable only for very high-value materials such as pharmaceuticals.
Sources: en.wikipedia.org
Strategic Cyber Security, ISBN 978-9949-9040-7-5, 169 pages Halpern, Sue, "The Drums of Cyberwar" (review of Andy Greenberg, Sandworm: A New Era of Cyberwar and the Hunt for the Kremlin's Most Dangerous Hackers, Doubleday, 2019, 348 pp.), The New York Review of Books, vol. LXVI, no. 20 (19 December 2019), pp. 14, 16, 20. Harris, Shane (2014). @War: The Rise of the Military-Internet Complex. Eamon Dolan/Houghton Mifflin Harcourt. ISBN 978-0-544-25179-3. Hunt, Edward (2012). "US Government Computer Penetration Programs and the Implications for Cyberwar". IEEE Annals of the History of Computing. 34 (3): 4–21. Bibcode:2012IAHC...34c...4H. doi:10.1109/mahc.2011.82. S2CID 16367311. Kestner, Peter (2024). The Art of Cyber Warfare: Strategic and Tactical Approaches for Attack and Defense in the Digital Age (1st ed.). Wiesbaden: Springer. pp. XX, 292. doi:10.1007/978-3-658-43879-1. ISBN 978-3-658-43879-1. Janczewski, Lech; Colarik, Andrew M. (2007). Cyber Warfare and Cyber Terrorism. Idea Group Inc (IGI). ISBN 978-1-59140-992-2. Rid, Thomas (2012). "Cyber War Will Not Take Place". Journal of Strategic Studies. 35 (1): 5–32. doi:10.1080/01402390.2011.608939. S2CID 153828543. Springer, Paul J. (2025). Encyclopedia of Cyber Warfare (2nd ed.). New York: Bloomsbury Academic. p. 464. ISBN 9781440881619. Woltag, Johann-Christoph: 'Cyber Warfare' in Rüdiger Wolfrum (Ed.) Max Planck Encyclopedia of Public International Law (Oxford University Press 2012).
=== Sites for infusion sets === Infusion sets are most commonly placed on the abdomen, in a roughly semicircular area around and below the navel. Other sites include the upper leg, upper buttocks, hips, upper arms and lower back. Insulin absorption may vary from site to site, and therefore medical advice is required.
== Definition == The term secretome was coined by Tjalsma and colleagues in 2004 to denote all the factors secreted by a cell, along with the secretory pathway constituents. In 2010, this definition of secretome was revised to include only proteins secreted into the extracellular space. Related concepts include the matrisome, which is the subset of the secretome that includes extracellular matrix proteins and their associated proteins; the receptome, which includes all membrane receptors, and the adhesome, which includes all proteins involved in cell adhesion.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.